Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of bintrafusp alfa (M7824) monotherapy in biliary tract cancer after failure or intolerance of first-line chemotherapy
CTR20191364Phase 2Completed
- Sponsor
- Merck Serono
- Start
- Jul 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of bintrafusp alfa in biliary cancer, sponsored by Merck Serono. Started Jul 2019; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
biliary cancer
Beyond the preview
Go deeper on CTR20191364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191364.